Bradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.
Bradley McGregor, MD, senior physician at Dana-Farber Cancer Institute, and director of Clinical Research at the Lank Center for Genitourinary Oncology, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial (NCT04413123) of cabozantinib (Cabometyx), nivolumab (Opdivo), and ipilimumab (Yervoy) for the treatment of patients with renal cell carcinoma with variant histologies (RCCvh).
Patients with metastatic RCCvh were eligible for enrollment in the study if they had an ECOG performance status of 0-1. Patients also were eligible if they had received 1 prior line of therapy, excluding immunotherapy or cabozantinib.
Once enrolled, patients underwent a baseline biopsy and were treated with nivolumab 3 mg/kg and ipilimumab 1 mg/kg via intravenous (IV) infusion every 3 weeks for 4 cycles. This was then followed by IV nivolumab 480 mg every 4 weeks. Further, patients received cabozantinib continuously at a dose of 40 mg daily, and investigators assessed the primary end point of objective response rate by RECIST 1.1, and safety as a secondary end point.
Transcription:
0:10 | When we think about renal cell carcinoma, there's been a ton of advances in the treatment of renal cell carcinoma. However, a lot of those have been related to clear cell renal cell carcinoma, which is the most common type of kidney cancer accounting for 80% of renal cell carcinomas. But we know there's 20% of patients who present with RCC with variant histologies, what we call, non-clear cell, and we have been looking to make advances in that field.
0:36 | For a long time, there have been incremental advances, but there have been some exciting advances recently. We were building upon what we saw with COSMIC-313 [NCT03937219] with [nivolumab, ipilimumab, and cabozantinib], vs nivolumab and ipilimumab, and tried to bring that triplet into RCC with variant histology.
0:49 | This was a single arm, phase 2 trial which took 40 patients with renal cell carcinoma with variant histology who have received up to 1 prior to therapy, excluding immunotherapy or cabozantinib. They went on to receive induction with nivolumab and ipilimumab, and cabozantinib 40 mg daily, followed by nivolumab with cabozantinib until unacceptable toxicity or progression.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More